| Name | Title | Contact Details |
|---|
The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit – and is best told through our patients, our employees and the communities in which we serve. Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most. That foundation has not only delivered significant results, but is a reflection of our ability to convert entrepreneurism and innovation into business success. We are focused on the transformation of Mundipharma`s business in the important Emerging Markets – by leveraging our global leadership in pain and through a shared spirit of innovation, we are building a growing presence in antisepsis, respiratory, oncology, consumer healthcare and other specialty areas. Our unique approach to partnerships has given us the opportunity to establish a strong market presence that covers the world`s pharmaceutical markets. Today we are an innovative company, with more than 4,500 employees across the Emerging Markets and a distribution network covering six continents. And this is just the beginning of our story in this region.
Aptalis Pharma is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Macroflux Corp. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Central Wyoming Counseling Center is a non-profit Community Mental Health and Substance Abuse Treatment Center that is dedicated to helping Residents of Wyoming.
Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.